168 related articles for article (PubMed ID: 20386525)
1. Molecular therapy of pancreatic cancer.
Plentz RR; Manns MP; Greten TF
Minerva Endocrinol; 2010 Mar; 35(1):27-33. PubMed ID: 20386525
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Oberstein PE; Saif MW
JOP; 2011 Mar; 12(2):96-100. PubMed ID: 21386629
[TBL] [Abstract][Full Text] [Related]
3. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Burris H; Rocha-Lima C
Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
[TBL] [Abstract][Full Text] [Related]
6. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
7. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
8. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Cartwright T; Richards DA; Boehm KA
Cancer Control; 2008 Oct; 15(4):308-13. PubMed ID: 18813198
[TBL] [Abstract][Full Text] [Related]
9. New directions in the management of advanced pancreatic cancer: a review.
Rocha-Lima CM
Anticancer Drugs; 2008 Jun; 19(5):435-46. PubMed ID: 18418211
[TBL] [Abstract][Full Text] [Related]
10. Palliative chemotherapy for pancreatic malignancies.
Mehta SP
Surg Clin North Am; 2010 Apr; 90(2):365-75. PubMed ID: 20362792
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in locally advanced or metastatic breast cancer.
Gradishar WJ
Expert Opin Investig Drugs; 2012 Aug; 21(8):1177-91. PubMed ID: 22616580
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
Rivera F; López-Tarruella S; Vega-Villegas ME; Salcedo M
Cancer Treat Rev; 2009 Jun; 35(4):335-9. PubMed ID: 19131170
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced pancreatic cancer.
Ducreux M; Boige V; Malka D
Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349
[TBL] [Abstract][Full Text] [Related]
14. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
[TBL] [Abstract][Full Text] [Related]
15. Metastatic pancreatic cancer: old drugs, new paradigms.
Conroy T; Gavoille C; Adenis A
Curr Opin Oncol; 2011 Jul; 23(4):390-5. PubMed ID: 21505335
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Kibble A
IDrugs; 2007 Aug; 10(8):520-2. PubMed ID: 17665322
[No Abstract] [Full Text] [Related]
17. [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
Conroy T; Mitry E
Bull Cancer; 2011 Dec; 98(12):1439-46. PubMed ID: 22133915
[TBL] [Abstract][Full Text] [Related]
18. New developments in pancreatic cancer treatment.
Krug S; Michl P
Minerva Gastroenterol Dietol; 2012 Dec; 58(4):427-43. PubMed ID: 23207616
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic cancer: an update.
Kindler HL
Curr Oncol Rep; 2007 May; 9(3):170-6. PubMed ID: 17430687
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
